Publisher
Springer International Publishing
Reference25 articles.
1. Jaros J, Hendricks AJ, Shi VY, Lio PA. A practical approach to recalcitrant face and neck dermatitis in atopic dermatitis. Dermatitis. 2020;31(3):169–77. https://doi.org/10.1097/DER.0000000000000590.
2. Din ATU, Malik I, Arshad D, Din ATU. Dupilumab for atopic dermatitis: the silver bullet we have been searching for? Cureus. 2020;12(4):e7565. https://doi.org/10.7759/cureus.7565.
3. D'Ippolito D, Pisano M. Dupilumab (Dupixent): an interleukin-4 receptor antagonist for atopic dermatitis. P T. 2018;43(9):532–5. PMID: 30186024; PMCID: PMC6110636.
4. DUPIXENT (Dupilumab). injection-Accessdata.fda.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf. Accessed 25 Aug 2022.
5. Dalia Y, Johnson SM. Case report: first reported case of facial rash after dupilumab therapy. Pract Dermatol. 2018;15:25–6.